Activation of the P2X7 ion channel by soluble and covalently bound ligands

Nicole Schwarz · Ralf Fliegert · Sahil Adriouch · Michel Seman · Andreas H. Guse · Friedrich Haag · Friedrich Koch-Nolte

Received: 5 April 2008 / Accepted: 16 September 2008 / Published online: 3 March 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract The homotrimeric P2X7 purinergic receptor has sparked interest because of its capacity to sense adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) released from cells and to induce calcium signaling and cell death. Here, we examine the response of arginine mutants of P2X7 to soluble and covalently bound ligands. High concentrations of ecto-ATP gate P2X7 by acting as a soluble ligand and low concentrations of ecto-NAD gate P2X7 following ADP-ribosylation at R125 catalyzed by toxin-related ADP-ribosyltransferase ART2.2. R125 lies on a prominent cysteine-rich finger at the interface of adjacent receptor subunits, and ADP-ribosylation at this site likely places the common adenine nucleotide moiety into the ligand-binding pocket of P2X7.

Keywords ADP-ribosyltransferases · Ecto-nucleotides · Ion channels · Purine receptors

Introduction

Nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP) are the universal currencies of energy metabolism in all kingdoms of life. Following their release from cells, ATP and NAD can function as extracellular signaling molecules [1–3]. The extracellular actions of ATP are mediated through ionotropic P2X and metabotropic P2Y purinergic receptors [4–7]. Extracellular NAD serves as a substrate for cell surface ADP-ribosyltransferases (ARTs) that catalyze the post-translational modification of membrane proteins by ADP-ribose [8–10]. The concentrations of extracellular ATP and NAD are controlled by ATP- and NAD-hydrolyzing ecto-enzymes such as CD39 and CD38 [11, 12].

Mammalian cell surface ARTs transfer the ADP-ribose moiety from NAD onto arginine residues on secreted and membrane proteins including defensin 1, integrins, and the P2X7 receptor [13–15]. These mammalian ARTs are closely related in structure and function to bacterial toxin ARTs like the C2 and C3 toxins of Clostridium botulinum [16–20]. ADP-ribosylation can either inactivate the function of the target protein as in the case of actin and elongation factor 2 [21, 22], or activate target protein function as in the case of the P2X7 receptor [15, 23].

Among purinergic receptors, P2X7 is widely expressed on immune cells and plays a crucial role in the processing and release of the leader-less cytokines IL-1β and IL-18 [24–29]. P2X7 has been implicated in the activation of the inflammasome, the killing of intracellular microorganisms by macrophages, apoptosis of T cells, cell fusion, and shedding of the CD62L homing receptor [15, 30–38].

Activation of P2X7 either by high concentrations of ecto-ATP or by ADP-ribosylation induces P2X7 to form a nonselective cation channel, allowing influx of calcium, followed rapidly by exposure of phosphatidylserine on the outer leaflet of the plasma membrane [15, 39–42].
Prolonged activation of P2X7 induces the formation of a nonselective pore, recently identified as pannexin 1, that allows the passage of large DNA-staining dyes such as YO-PRO-1, followed by membrane blebbing, mitochondrial dysfunctioning, DNA fragmentation, release of lactate dehydrogenase, and cell death [15, 40, 41, 43–45].

Like other P2X receptors, P2X7 is thought to form trimers [46]. Each subunit has two transmembrane regions (Tm1 and Tm2) and cytosolic N- and C-termini [5–7]. The extracellular ligand-binding domain contains approximately 280 amino acid residues (aa 47–329), including ten conserved cysteine residues that are probably engaged in intrachain disulfide bonding [47, 48]. No 3D structure is yet available for any of the P2X purinergic receptors, but modern prediction programs such as PSI-PRED [49] can pinpoint potential secondary structures and provide insight into the local structural context of amino acid residues [23].

The extracellular domain of P2X7 contains 11 arginine residues that are strictly conserved in mouse, rat, and human P2X7 (Fig. 1). Residues R125 and R151 lie on the side and at the tip of a conspicuous cysteine-rich “finger” that is connected by three closely spaced disulfide bridges. Residue R206 is flanked by two potential N-linked glycosylation sites. Residues R307 and R316 are located in a β-stranded region upstream of Tm2. The other conserved arginine residues lie outside of well-defined secondary structure units, consistent with a location in loops on the surface of the protein, as would be expected for charged amino acid residues.

**Results and discussion**

Lysine substitutions at R206, R276, and R277 result in enhanced ATP sensitivity, and lysine substitution at R294 results in loss of ATP sensitivity

In order to explore the potential functional significance of the conserved arginine residues in the extracellular domain of P2X7 and in order to identify the target residue(s) for ADP-ribosylation, we analyzed the effects of substituting each of these arginines for lysine or alanine on expression and function of P2X7 in transfected human embryonal kidney (HEK) cells. Cell surface expression levels were assessed 20 h post-transfection by flow cytometry using three different fluorochrome-conjugated antibodies that recognize P2X7 in native conformation [15, 50]. All arginine to lysine mutants except for mutant R307K were clearly detectable on the cell surface [23]. Other conservative substitutions of this residue resulted in low expression levels, indicating that an arginine at this position is required for proper expression and/or stability of the protein. Mutants R151K and R151A were detectable with monoclonal antibody Hano43 but lost reactivity with mAb Hano44 and with the anti-P2X7 serum K1G, consistent with the notion that the cysteine-rich region containing R151 forms a finger-like structure accessible to antibodies [23].

Using a sensitive live cell imaging technique, we assessed calcium responses and membrane blebbing of HEK cells attached to cover slips 20 h after transfection with wild-type and mutant P2X7 (Fig. 2). When cells were perfused for 3-min periods with increasing doses of ATP, we observed small transient responses in untransfected and mock-transfected HEK cells likely mediated by metabotropic P2Y receptors (panel 1). Typically, these transient responses were induced at low doses of ATP (10 μM, and in some cells even at 1 μM). Although ATP mediates a P2X7-independent response in HEK cells, the responses mediated by P2X7 could be clearly distinguished from the former: cells expressing wild-type P2X7 showed a strong sustained response to 1 mM ATP, which subsided only after removal of ATP (panel 2). Most P2X7 mutants showed responses similar to wild-type P2X7 (panels 3–6, 8, and 13), whereas cells expressing R294K and R307K did not show any responses besides the transient responses also seen in mock-transfected cells (panels 11, 12). Strikingly, cells expressing R276K or R277K showed sustained responses already to 100 μM ATP. Moreover, in these cells, calcium responses were maintained at elevated levels during washout of ATP (panels 9 and 10). Similarly, HEK cells expressing R206K initiated sustained calcium responses already to 100 μM ATP, albeit with a slight delay (panel 7).

Similar results were obtained using fluorescence-activated cell sorting (FACS)-based assays for ATP-induced changes in forward and side scatter (Fig. 3) by HEK cells harvested 20 h after transfection. Six mutants—R53K, R125K, R151K, R178K, R230K, and R316K—displayed ATP potencies in these assays similar to wild-type P2X7 (EC50 150–300 μM) (Fig. 3b, panel 2). Mutant R294K, which is expressed on the cell surface, and mutant R307K, which is not expressed on the cell surface completely lacked any detectable response to ATP (Fig. 3a, panel 2 and Fig. 3b, panel 1). The three mutants, R206K, R276K, and R277K, again showed ATP potencies that were enhanced five- to 20-fold compared to wild-type P2X7 (EC50 7.5–30 μM) (Fig. 3b, panel 3). Similar results were obtained for ATP-induced exposure of phosphatidylserine and formation of pores permeable to the DNA staining dye YO-PRO-1 (data not shown and [23]).

These results underscore the functional importance of residues R294 and R307. The finding that mutant R294K was expressed at the cell surface at wild-type levels, but did not show any detectable responses to ATP or NAD, is in accord with previous studies reporting loss of function upon mutation of the corresponding residues to alanine or lysine in human P2X1 (R292), rat P2X2 (R291), and mouse P2X7.
The connectivity of cysteine residues (in red) corresponds to that proposed for P2X1 and P2X2 [6]. The conserved arginine (R) residues in the ectodomain are indicated by yellow diamonds, the natural allelic polymorphism in the cytosolic domain [70] that distinguishes C57BL/6 mice from wild-type mice is indicated by a pink circle. Potential glycosylation sites are indicated by green triangles and predicted β-strands by blue arrows. The sequences in the alignment of mouse, rat, and human P2X7 are truncated five residues downstream of Tm2. Secondary structures predicted with PSIPRED [49] are indicated above the alignment (H helix; E extended β-strand; C coil, unstructured). Structure units with a confidence >8 are highlighted in blue. Identical amino acid residues are indicated by asterisks, strongly and weakly conserved residues by colons and periods, respectively. Predicted transmembrane domains and conserved cysteine residues are in red, potential N-linked glycosylation sites are in green. The 11 conserved arginine residues in the ectodomain are highlighted in yellow and their positions in residue number (for mouse P2X7) are indicated above the alignment.
R294 forms part of a contiguous asparagine–phenylalanine–arginine (NFR) motif that has been proposed to coordinate binding of the adenine and ribose moieties [6]. R307, on the other hand, seems to be important for proper folding and/or stability of the receptor, since mutation of this residue to any of five other residues tested (A, K, Q, E, and H) had a strong negative impact on cell surface expression. A natural allelic variant, R307Q, has been described previously for human P2X7 [53], which also did not show any detectable ATP response.

Lysine substitutions at R206, R276, and R277 result in enhanced sensitivity to gating by ADP-ribosylation.

We further assayed whether activation of P2X7 by ADP-ribosylation can be observed in HEK cells co-transfected with ART2 and each of the 11 P2X7 arginine mutants (Fig. 4). Live cell calcium imaging experiments in which cells were perfused for 3-min periods with increasing doses of NAD revealed a small transient response to high NAD concentrations (250 μM) in untransfected and mock-transfected HEK cells, possibly mediated by the metabotropic P2Y11 receptor [54]. Strong sustained responses to 100-fold lower concentrations of NAD (2.5 μM) were detected in the case of cells co-transfected with ART2.2 and mutants R206K, R276K, or R277K (Fig. 4, panels 7, 9, 10), i.e., the same mutants that had shown dramatically enhanced sensitivity to ATP in the previous assays (Fig. 2, panels 7, 9, 10 and Fig. 3b, panel 3). Further, HEK cells co-transfected with ART2.2 and wild-type P2X7 or P2X7 mutants with wild-type-like sensitivities to ATP did...
not show any detectable responses, even to saturating concentrations of NAD (panels 2–6, 8, 13 in Figs. 2 and 4).

When comparing the responses of P2X7 to the soluble ligand ATP vs. the immobilized ligand ADP-ribose (generated by ART2.2 upon exposure of cells to NAD), several points are worth noting: Firstly, much lower concentrations of NAD (2.5 μM) than ATP (100 μM) are required to activate the gain-of-function mutants R206K, R276K, and R277K. A similar difference in the sensitivity of wild-type P2X7 to activation by ATP vs. NAD has been noted previously for primary T cells [15]. This much higher sensitivity to low concentrations of NAD vs. ATP most likely reflects a higher stability and consequently higher local concentration of a covalently bound vs. soluble ligand. Secondly, and in accord with this notion, calcium signals subside more slowly during washout of saturating concentrations of NAD than ATP (panels 7, 9, and 10 in Fig. 2 vs. Fig. 4). Similarly, PS exposure by primary T cells induced by short pulse treatments of ATP was readily reversed but the effects induced by pulse treatments with NAD were not [15]. Thirdly, in ART2.2 co-transfected HEK cells, neither wild-type P2X7 nor any of the six mutants with wild-type-like responses to ATP showed any detectable responses to NAD (Fig. 4, panels 2–6, 8, and 13), even at concentrations far above the levels required for saturating ADP-ribosylation of proteins on the HEK cell surface. Most likely, the different sensitivities of P2X7 to activation by ADP-ribosylation in HEK cells vs. primary T cells reflect differences in these cells in proteins and/or lipids in the plasma membrane available for interaction with P2X7 [55, 56]. Indeed, even different subsets of T cells evidently differ in their sensitivity to P2X7 activation, with regulatory T cells being particularly sensitive [57].

ADP-ribosylation at R125 in the cysteine-rich finger provides a ligand for the binding site while ADP-ribosylation at R133 does not.

Analysis of radiolabeling of P2X7 mutants in ART2.2 co-transfected HEK cells using radioactive [32P]-NAD as substrate allowed us to identify R125 and the nearby nonconserved residue R133 as the sole targets for ADP-ribosylation in P2X7 [23]. Both of these residues are located in a prominent finger-like cysteine-rich region (Fig. 1). The NAD-mediated activation of P2X7 in HEK cells co-transfected with the gain-of-function mutant R276K and ART2.2 allowed us to directly assess whether ADP-ribosylation of P2X7 itself or ADP-ribosylation of other membrane proteins was responsible for gating of P2X7 [23]. Replacement of R125 by lysine in R276K abolished responses to NAD, while replacement of R133 by lysine did not. Importantly, substitution of residues R125 or R133 with lysine, either alone or in combination, did not alter the sensitivity to ATP, indicating that the ligand-binding site itself was not affected by these substitutions. These results demonstrated that ADP-ribosylation at R125 gates P2X7, whereas ADP-ribosylation at R133 does not [23]. The observation that the R125K mutant could not be activated...
by ADP-ribose groups bound either to R133 or attached to other target proteins on the cell surface effectively rules out the model proposed by Kawamura and coworkers, in which P2X7 was proposed to be activated by ADP-ribosyl groups presented on neighboring ADP-ribosylated proteins [35].

In analogy to glutamate and nicotinic receptors, it has been proposed that the ligand-binding site of P2X purinergic receptors is located at the interface of two adjacent receptor subunits [5, 6]. Our model for the activation of P2X7 by ADP-ribosylation is in line with this notion (Fig. 5). We propose that the ADP-ribose moiety covalently attached to R125 provides a ligand that fits into the binding site between two adjacent P2X7 subunits. This model accounts for the resistance of P2X7 to activation by covalently linked etheno-ADP-ribose and other ADP-ribose analogues carrying modifications of the adenosine moiety, as these analogues would not be expected to fit into the ligand-binding site [15]. Moreover, our model accounts for the finding that ADP-ribosylation at the second target site, R133, does not activate P2X7, as the ADP-ribose unit attached to R133 would be out of reach of the ligand-binding site. Further, our model is in accord with the notion that residue R125 lies at the interface of two neighboring subunits. This is consistent with recent findings for the corresponding histidine residue in P2X2, H120 [58]. A disulfide bond was formed between adjacent P2X2 subunits when this residue and residue H213 (S215 in P2X7) were mutated to cysteine.

Our results further indicate that the cysteine-rich region plays an important functional role and may form an exposed finger-like structure. This region is accessible to ART2.2 (i.e., can be ADP-ribosylated at R125 and R133) as well as to antibodies, with residue R151 at the tip of the finger-forming part of the epitope recognized by both, the monoclonal rat antibody Hano43 and by the polyclonal

Fig. 4 Potency of ADP-ribosylation to induce calcium flux in HEK cells transiently transfected with P2X7 variants. HEK cells were co-transfected with expression constructs for mRFP, ART2.2, and wild-type or mutant P2X7 receptors. Twenty hours post-transfection, cells were loaded with the calcium-sensitive fluorochrome Fura-2 before live cell imaging by fluorescence microscopy as in Fig. 2. At the indicated times, the perfusion buffer (37°C) was changed to subject cells to increasing doses of NAD. Gray lines show single cell tracings, red lines the calculated mean.
rabbit serum K1G. Moreover, recent reports indicate that mutation of other residues in this region can result in gain-of-function P2X7 (A127K in mouse P2X7 and H155Y in human P2X7) [59, 60] or affect the inhibition of P2X7 function by zinc and magnesium (H130A in rat P2X7) [61] (see also Fig. 6, below).

Comparison of the P2X7 mutants analyzed here with those of other P2X receptors

Table 1 provides a comparison of the mouse P2X7 mutants analyzed in the present study with those of previous mutagenesis studies on other P2X receptors (summarized in [6, 7, 62]). The only arginine that, when mutated, impairs ATP potency in all P2X receptors analyzed so far is residue R294. Mutation of the corresponding residues in human P2X1 (R292) and in rat P2X2 (R291) also resulted in dramatic reduction in ATP potency [51, 52]. This residue forms part of a conserved NFR motif found in all P2X receptors and has been proposed to coordinate the adenosine and ribose moieties [6]. The results of a recent, elegant mutagenesis study with rat P2X1 strongly indicate that this motif lies at the interface of two adjacent receptor subunits near the ATP-binding site: simultaneous cysteine substitutions of the corresponding phenylalanine residue (F291) and lysine 68 (corresponding to K64 of P2X7 see Fig. 5) allowed the formation of an intersubunit disulfide bond, which was inhibited by ATP [63].

Fig. 6 Summary of mutagenesis data for P2X receptors in the region of the cysteine-rich finger. The arginine residues that serve as targets for ADP-riboylation in mouse P2X7 [23], rat, and human P2X7 (our own unpublished observations) are highlighted in cyan. Conserved cysteine residues are highlighted in yellow. Amino acid residues that, when mutated, result in a gain-of-function are shown in bold and are highlighted in green [59, 60]. Residues that alter the sensitivity of the receptor to zinc, copper, and/or magnesium are shown in bold red [58, 59, 61, 77]. The positions of the cysteines (numbering for mouse P2X7) are indicated on top, the proposed connectivity [6] is indicated below. mm = Mus musculus, hs = Homo sapiens, rn = Rattus norvegicus, sm = Schistosoma mansoni, dd = Dictyostelium discoideum.
Table 1  Summary of mutant phenotypes

| Residues corresponding to those analyzed in this study | mP2X7 | hP2X7 | hP2X1 | rP2X2 | rP2X4 |
|-------------------------------------------------------|-------|-------|-------|-------|-------|
| R53K                                                  | R53   | T57   | D57   | E56   |
| R125K                                                 | R125  | G123  | H120A | A122  |
| R151K                                                 | R151  | K148  | H146  | R148  |
| R178K                                                 | R178  | R175  | N173  | Q175  |
| R206K                                                 | R206  | R202A | K200  | K203  |
| R230K                                                 | R230  | Q231  | K228A | R231  |
| R276K                                                 | R276  | H277  | R274  | R277  |
| R277K                                                 | R277  | G278  | R275  | R277K |
| R294K                                                 | R294  | R292A | R290A | R295  |
| R307K                                                 | R307Q | R305A | R304A | R309  |
| R316K                                                 | R316  | R314A | R313  | R318K |
| Other positively charged residues with altered ATP potency |
| K64                                                   | K66   | K68A  | K69A  | K67   |
| K66                                                   | K66   | K70A  | K71A  | K69   |
| K193                                                  | K193A | K190A | K188A | K190R |
| K311                                                  | K311A | K309A | K308A | K313  |

*Italic* mutants with no or only small changes in ATP sensitivity, *bold* mutants with strongly reduced ATP potency, *bold italics* and *underlined* gain-of-function mutants, *upright (without emphasis)* residues that to our knowledge have not been tested by mutagenesis. References for: human P2X7 [53, 60, 74], human P2X1 [51], rat P2X2 [52, 64, 75], and rat P2X4 [65]

Other arginine mutants, evidently, affect only certain members of the P2X family. For example, mutation of the residue corresponding to R307 (which seems to be essential for the stability and cell surface expression of mouse P2X7) resulted in a loss of function of human P2X7 (R307Q) and of rat P2X2 (R304A), but not of human P2X1 (R305A) [52, 53]. Mutation of the residue corresponding to R316 (which impaired cell surface expression but not ATP potency of mouse P2X7, see above) did not affect the ATP potency of human P2X1 (R314A) [51]. Mutation of residue R230 to K or A did not affect the function of mouse P2X7, whereas mutation of the corresponding residues (K228A) moderately impaired the ATP potency of rat P2X2 [64].

At the position corresponding to the R206K gain-of-function mutant of mouse P2X7, human P2X1 (R202) and hP2X2 (R206) also carry an arginine residue, while hP2X2 (K200) and hP2X4 (K203) carry a lysine residue. Mutation of R202 did not affect the ATP potency of human P2X1 [51]. The arginine doublet at the other two gain-of-function mutants of mouse P2X7 (R276, R277) is conserved in rat P2X2 (R274/R275), rat P2X4 (R277/R278), and human P2X7 (R276/R277), but not in human P2X1 (H277/G278). Mutation of the downstream arginine residue in this doublet in rat P2X4 resulted either in a slightly enhanced ATP potency (R278K) or in a dramatically reduced in ATP potency (R278A) [65].

The arginine residues in the cysteine-rich finger of mouse P2X7, which serve as targets for ADP-ribosylation in mouse P2X7, are only partially conserved in rat and human P2X7, where they also function as targets for ADP-ribosylation (our own unpublished observations). However, these residues are conserved neither in other mammalian P2X receptors nor in the distant P2X orthologs of *Schistosoma mansoni* [66, 67] and *Dictyostelium discoideum* (Fig. 6). Note that the distal portion of the finger is missing in the *Dictyostelium* P2X, recently shown to be expressed in an intracellular organelle (the contractile vacuole) where it plays a crucial role in cell volume regulation [68]. The absence of suitable targets for ADP-ribosylation in other P2X receptors indicates that gating by ADP-ribosylation is unique to P2X7. It is tempting to speculate that there may be an evolutionary link between the comparatively low sensitivity of P2X7 to gating by the soluble ligand ATP and its unique capacity to be gated by a covalently tethered ligand.

### Materials and methods

#### Cloning of expression vectors and cell transfections

Expression vectors for wild-type ART2.2 and wild-type or mutant P2X7 were cloned as described previously [23, 69–71]. The expression construct for monomeric red fluorescent protein (mRFP) was from Clontech. Expression constructs (5 μg per 10⁶ cells) were transfected into HEK cells with the jet PEI transfection reagent (Q-Biogen). Anti-P2X7 antibodies were generated by genetic immunization as described previously [50, 71]. Antibodies were conjugated to Alexa-488 according to the manufacturer’s (Molecular Probes/Invitrogen) instructions.

#### FACS analyses

Cells were harvested by trypsinization 20 h post-transfection, followed by staining with Alexa-488-conjugated antibodies (0.2 μg/2×10⁵ cells/100 μl). Separate aliquots of cells were washed and then incubated in the absence or presence of the indicated concentrations of ATP in 10 mM HEPES pH 7.5, 140 mM NaCl, 5 mM KCl, 10 mM glucose for 60 min at 37°C. Cells were washed before FACS analyses using a FACS-Calibur and the Cellquest-Pro software (Becton Dickinson).

#### Calcium imaging by fluorescence microscopy

For ratiometric calcium imaging [72, 73], HEK cells were co-transfected with expression vectors for P2X7, ART2.2, and mRFP as indicated and plated at low density on glass bottom culture dishes (35 mm, MatTek, Ashland, USA).
Twenty hours post-transfection, the culture medium was removed gently and replaced with prewarmed buffer (15 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1.35 mM CaCl₂, 10 mM glucose, 0.1% BSA), containing 4 μM Fura-2/AM (Calbiochem) for 30 min at 37°C. Imaging of cells was performed with a Leica DM-IRBE fluorescence microscope equipped with perfusion system (Warner Instruments, Hamden, USA) and a 40× objective (1.3 numerical aperture). Cells were continuously perfused with prewarmed (37°C) buffer (see above) containing the indicated concentrations of ATP or NAD. Alternating excitation at 340 and 380 nm was achieved using a monochromator system (Polychrome II; TILL Photonics, Graefelfing, Germany). Two images were acquired every 5 s with a grayscale CCD camera (type C4742-95-12NRB; Hamamatsu, Enfield, UK). Raw data images were stored on a hard disc, and ratio images (340/380 nm) were calculated using Openlab software (v3.09; Improvision, Tübingen, Germany).

Acknowledgments This work was supported by grants from the Deutsche Forschungsgemeinschaft (grants No. 310/6 and 310/8 to FKN and FH; grants GU 360/7 and 360/9 to AHG). SA was the recipient of stipends from the Fondation pour la Recherche Médicale and from the Deutsche Forschungsgemeinschaft. We thank Fenja Braasch, Gudrun Dubberke, and Fabienne Seyfried, Hamburg, for excellent technical assistance. FKN, FH, MS, and AHG designed and supervised this study. SA cloned the P2X7 mutants and performed the experiments shown in Fig. 3, NS and RF performed the experiments shown in Figs. 2 and 4. FKN wrote the paper. We thank Drs. Bernhard Fleischer, Hans-Willi Mittmüller, and Roland Martin, Hamburg, and Dr. Olivier Boyer, Rouen, for critical reading of the manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Ziegler M (2000) New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 267:1550–1564
2. la Sala A, Ferrari D, Di Virgilio F, Idzko M, Norgauer J, Girolomoni G (2003) Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol 73:339–349
3. Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. Nature 442:527–532
4. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR (2001) Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587–600
5. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013–1067
6. Vial C, Roberts JA, Evans RJ (2004) Molecular properties of ATP-gated P2X receptor ion channels. Trends Pharmacol Sci 25:487–493
7. Stojilkovic SS, Tomic M, He ML, Yao Z, Koshimizu TA, Zemkova H (2005) Molecular dissection of purinergic P2X receptor channels. Ann N Y Acad Sci 1048:116–130
8. Corda D, Di Girolamo M (2003) Functional aspects of protein mono-ADP-ribosylation. EMBO J 22:1953–1958
9. Koch-Nolte F, Adiouch S, Bannas P, Krebs C, Scheuplein F, Seman M, Haag F (2006) ADP ribosylation of membrane proteins: unveiling the secrets of a crucial regulatory mechanism in mammalian cells. Ann Med 38:188–199
10. Zolkiewska A (2005) Ecto-ADP-ribose transferases: cell-surface response to local tissue injury. Physiology (Bethesda) 20:374–381
11. Robson SC, Sevigny J, Zimmerman H (2006) The E-NTPase family of ectonucleotidases: structure-function relationships and pathophysiological significance. Purinergic Signal 2:409–430
12. Krebs C, Adiouch S, Braasch F, Koestner W, Leiter EH, Seman M, Lund FE, Oppenheimer N, Haag F, Koch-Nolte F (2005) CD38 controls ADP-ribosyltransferase-2-catalyzed ADP ribosylation of T cell surface proteins. J Immunol 174:3298–3305
13. Nemoto E, Yu Y, Dennert G (1996) Cell surface ADP-ribosyltransferase regulates lymphocyte function-associated molecule-1 (LFA-1) function in T cells. J Immunol 157:3341–3349
14. Paone G, Wada A, Stevens LA, Matin A, Hirayama T, Levine RL, Moss J (2002) ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc Natl Acad Sci U S A 99:8231–8235
15. Seman M, Adiouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, Koch-Nolte F (2003) NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2activates the cytolytic P2X7 purinoceptor. Immunity 19:571–582
16. Koch-Nolte F, Reche P, Haag F, Bazan F (2001) ADP-ribosyltransferases: plastic tools for inactivating protein and small molecular weight targets. J Biotechnol 92:81–87
17. Mueller-Dieckmann C, Ritter H, Haag F, Koch-Nolte F, Schulz G (2002) Structure of the ecto-ADP-ribose transference ART2.2 from rat. J Mol Biol 322:687–696
18. Han S, Craig JA, Putnam CD, Carozzi NB, Tainer JA (1999) Evolution and mechanism from structures of an ADP-ribosylating toxin and NAD complex. Nat Struct Biol 6:932–936
19. Han S, Arvai AS, Clancy SB, Tainer JA (2001) Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. J Mol Biol 305:95–107
20. Schleberger C, Hochmann H, Barth H, Aktories K, Schulz GE (2006) Structure and action of the binary C2 toxin from Clostridium botulinum. J Mol Biol 364:705–715
21. Aktories K, Barmann M, Ohishi I, Tsuyama S, Jakobs KH, Habermann E (1986) Botulinum C2 toxin ADP-ribosylates actin. Nature 322:390–392
22. Jorgensen R, Merril AR, Yates SP, Marquez VE, Schwan AL, Boesen T, Andersen GR (2005) Exotoxin A–eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature 436:979–984
23. Adiouch S, Bannas P, Schwarz N, Flieger R, Guse AH, Seman M, Haag F, Koch-Nolte F (2008) ADP-ribosylation at R125 gates the cytolytic P2X7 purinoceptor. J Immunol 182:6124–6133
24. Perregaux D, Gabel CA (1994) Interleukin-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Biol Chem 269:15195–15203
25. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F (1997) Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol 159:1451–1458
26. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276:125–132
substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor. J Neurosci 27:1456–1466.

64. Nakazawa K, Ojima H, Ishii-Nozawa R, Takeuchi K, Ohno Y (2004) Amino acid substitutions from an indispensable disulfide bond affect P2X2 receptor activation. Eur J Pharmacol 483:29–35.

65. Yan Z, Liang Z, Tomic M, Obsil T, Stojilkovic SS (2005) Molecular determinants of the agonist binding domain of a P2X receptor channel. Mol Pharmacol 67:1078–1088.

66. Agboh KC, Webb TE, Evans RJ, Ennion SJ (2004) Functional characterization of a P2X receptor from Schistosoma mansoni. J Biol Chem 279:41650–41657.

67. Raouf R, Blais D, Seguela P (2005) High zinc sensitivity and pore formation in an invertebrate P2X receptor. Biochim Biophys Acta 1669:135–141.

68. Fountain SJ, Parkinson K, Young MT, Cao L, Thompson CR, North RA (2007) An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum. Nature 448:200–203.

69. Koch-Nolte F, Duffy T, Nissen M, Killeen N, Ablamunits V, Haag F, Leiter EH (1999) A new monoclonal antibody detects a developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation upon T cell activation. J Immunol 163:6014–6022.

70. Adrionch S, Dox C, Welge V, Seman M, Koch-Nolte F, Haag F (2002) Cutting edge: a natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. J Immunol 169:4108–4112.

71. Möller M, Jung C, Adrionch S, Dubberke G, Seyfried F, Seman M, Haag F, Koch-Nolte F (2007) Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation. Purinergic Signal 3:359–366.

72. Kunerth S, Mayr GW, Koch-Nolte F, Guse AH (2003) Analysis of subcellular calcium signals in T-lymphocytes. Cell Signal 15:783–792.

73. Gasser A, Glassmeier G, Fliegert R, Langhorst MF, Meinke S, Hein D, Kruger S, Weber K, Heiner I, Oppenheimer N, Schwarz JR, Guse AH (2006) Activation of T cell calcium influx by the second messenger ADP-ribose. J Biol Chem 281:2489–2496.

74. Worthington RA, Smart ML, Gu BJ, Williams DA, Petrou S, Wiley JS, Barden JA (2002) Point mutations confer loss of ATP-induced human P2X(7) receptor function. FEBS Lett 512:43–46.

75. Clyne JD, LaPointe LD, Hume RI (2002) The role of histidine residues in modulation of the rat P2X(2) purinoceptor by zinc and pH. J Physiol 539:347–359.

76. Evans RJ (2008) Orthosteric and allosteric binding sites of P2X receptors. Eur Biophys J 38:319–327.

77. Coddou C, Acuna-Castillo C, Bull P, Huidobro-Toro JP (2007) Dissecting the facilitator and inhibitor allosteric metal sites of the P2X4 receptor channel: critical roles of CYSL32 for zinc potentiation and ASP138 for copper inhibition. J Biol Chem 282:36879–36886.